PMID- 29491750
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240313
IS  - 1551-6776 (Print)
IS  - 2331-348X (Electronic)
IS  - 1551-6776 (Linking)
VI  - 23
IP  - 1
DP  - 2018 Jan-Feb
TI  - Sedation Protocol During Bevacizumab Intravitreal Injection in Preterm Infants 
      With Retinopathy of Prematurity.
PG  - 34-40
LID - 10.5863/1551-6776-23.1.34 [doi]
AB  - OBJECTIVES: This study describes outcomes of intravenous (IV) analgesics and 
      sedatives for bedside intravitreal bevacizumab injections for retinopathy of 
      prematurity. METHODS: This retrospective study included infants receiving 
      intravitreal bevacizumab injections between January 2012 and May 2016. Infants 
      were excluded if bevacizumab was administered under general anesthesia or for 
      incomplete records. Data collection included demographics, sedation and analgesia 
      regimen, and cardiopulmonary adverse events (AEs). The primary objective was to 
      identify the median doses of the IV analgesics and sedatives. The secondary 
      objectives included the number of patients with cardiopulmonary AEs and those 
      with procedure success, defined as procedure completion without interruption and 
      absence of interventions. RESULTS: Fifteen infants were included. Fourteen 
      (93.3%) were initiated on a fentanyl infusion at a median of 2 mcg/kg/hr (IQR, 
      2-3.6), and 12 (80%) received midazolam infusions at a median of 0.06 mg/kg/hr. 
      All patients received at least 1 IV neuromuscular blocker dose just prior to the 
      procedure. Only 2 patients (13.3%) required an increase in their fentanyl or 
      midazolam infusions. Procedure success was achieved in 13 patients (86.7%). Five 
      patients (33.3%) experienced 1 cardiopulmonary AE. One patient (6.7%) had a delay 
      in the procedure, and 1 patient (6.7%) required naloxone. Despite this, the 
      procedure was completed in all patients. CONCLUSIONS: Most received fentanyl and 
      midazolam infusions with a dose of vecuronium just prior to the procedure. 
      Thirteen (86.7%) met the criteria for procedure success. One-third experienced a 
      cardiopulmonary AE. Future studies are needed to identify the optimal agents and 
      route of administration for this procedure.
FAU - Miller, Jamie L
AU  - Miller JL
FAU - Johnson, Peter N
AU  - Johnson PN
FAU - Harkey, Kari
AU  - Harkey K
FAU - Siatkowski, R Michael
AU  - Siatkowski RM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pediatr Pharmacol Ther
JT  - The journal of pediatric pharmacology and therapeutics : JPPT : the official 
      journal of PPAG
JID - 101089851
PMC - PMC5823490
OTO - NOTNLM
OT  - bevacizumab
OT  - fentanyl
OT  - midazolam
OT  - neonatal intensive care unit
OT  - retinopathy of prematurity
COIS- Disclosure Dr Jamie Miller is on the speaker's bureau for Chiesi, USA, Inc. The 
      rest of the authors declare no conflicts or financial interest in any product or 
      service mentioned in the manuscript, including grants, equipment, medications, 
      employment, gifts, and honoraria. The authors had full access to all the data in 
      the study and take responsibility for the integrity of the data and the accuracy 
      of the data analysis.
EDAT- 2018/03/02 06:00
MHDA- 2018/03/02 06:01
PMCR- 2018/01/01
CRDT- 2018/03/02 06:00
PHST- 2018/03/02 06:00 [entrez]
PHST- 2018/03/02 06:00 [pubmed]
PHST- 2018/03/02 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.5863/1551-6776-23.1.34 [doi]
PST - ppublish
SO  - J Pediatr Pharmacol Ther. 2018 Jan-Feb;23(1):34-40. doi: 
      10.5863/1551-6776-23.1.34.